MedTrace Logo

Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma

NCT02875067 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-08-14

Study results available
· View outcomes & findings →

Summary

This trial is to assess the safety \& efficacy of the Combination of Pembrolizumab and Lenalidomide in the management of patients with Relapsed Hodgkin Lymphoma.

Conditions

  • Relapsed Hodgkin Lymphoma
  • Relapsed Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL

Pembrolizumab

DRUG

Lenalidomide

Sponsors & Collaborators

Principal Investigators

  • Catherine Diefenbach, MD · NYU Perlmutter Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-29
Primary Completion
2017-10-02
Completion
2017-10-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02875067 on ClinicalTrials.gov